Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 470

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 470
---
 EcoR1 Capital Funds. Oleg Nodelman is the control person of EcoR1 and may be deemed to share     
 dispositive voting power over the shares held by the EcoR1 Capital Funds. Mr. Nodelman and EcoR1 both disclaim beneficial ownership of all shares except to the extent of their pecuniary interest. The address for EcoR1 Capital LLC, the 
 EcoR1 Capital Funds and Oleg Nodelman is 357 Tehama Street #3, San Francisco, CA.                                                                                                                                                          |

| (5) | Consists of (i) 3,278,917 shares to be purchased in the PIPE Offering by Averill Master Fund, Ltd.                                                                                                                                                 
 (“Averill Master Fund”), and (ii) 421,083 shares to be purchased in the PIPE Offering by Averill Madison Master Fund, Ltd. (“Averill Madison Fund” and, together with Averill Master Fund, the “Averill Funds”). Suvretta                          
 Capital Management, LLC is the investment manager of the Averill Funds. Aaron Cowen is a control person of Suvretta Capital Management, LLC and as such may be deemed to beneficially own these shares. The principal business address of Suvretta 
 Capital Management, LLC is 540 Madison Avenue, 7th Floor, New York, NY 10022.                                                                                                                                                                      |

| (6) | Consists of 4,166,000 shares to be purchased in the PIPE Offering by OrbiMed Genesis Master Fund, L.P.                                                                                                                                                  
 (“Genesis”). OrbiMed Genesis GP LLC (“Genesis GP”) is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. OrbiMed Advisors exercises investment and voting power through a management committee                      
 comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis, except to the extent of its or his pecuniary interest therein if any. The address for each of Genesis is c/o 
 OrbiMed Advisors LLC, 601 Lexington Avenue, 54th Floor, New York, New York.                                                                                                                                                                             |

| (7) | Consists of (i) 22,869 shares of common stock held directly by Mr. Lennon; (ii) 236,809 shares                                                                                            
 issuable upon the exercise of options within 60 days of January 30, 2025; and (iii